AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
ACL - AUSTRALIAN CLINICAL LABS LIMITED
FNArena Sector :
Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.67
Index: ASX300 | ALL-ORDS
FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.67
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$3.63
04 Dec |
0.090 OPEN $3.52 |
2.54% HIGH $3.65 |
922,910 LOW $3.47 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 100% |
OTHER COMPANIES IN THE SAME SECTOR | |||
AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY23 Actual |
FY24 Actual |
FY25 Forecast |
FY26 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | 12.0 | 19.4 | xxx |
DPS (cps) | xxx | 12.0 | 13.6 | xxx |
EPS Growth | xxx | - 32.8% | 61.5% | xxx |
DPS Growth | xxx | - 14.3% | 13.3% | xxx |
PE Ratio | xxx | N/A | 19.5 | xxx |
Dividend Yield | xxx | N/A | 3.6% | xxx |
Div Pay Ratio(%) | xxx | 99.8% | 70.0% | xxx |
Last ex-div: 28/03 - ex-div 3c (franking 100%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 12.0 |
DPS All | xxx | xxx | xxx | xxx | xxx | 12.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 689.7 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 89.4 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 159.6 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 3.47 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 13.68 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 6.22 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 4.08 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 13.68 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 11.66 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 133.1 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 105 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 204 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 309 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 159 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 27 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 2.81 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 6.5 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 0.94 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 551 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 82 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
ACL STOCK CHART
FNArena News on ACL
1 |
Rudi’s View: Banks, Miners & Quality Small CapsSep 26 2024 - Rudi's View |
2 |
August Result Season 2024: The WrapSep 24 2024 - Feature Stories |
3 |
Weekly Ratings, Targets, Forecast Changes – 13-09-24Sep 16 2024 - Weekly Reports |
4 |
Rudi’s View: Key Picks, Best Buys & Conviction CallsSep 12 2024 - Rudi's View |
5 |
FNArena Corporate Results Monitor – 30-08-2024Aug 30 2024 - Australia |
Latest Healthcare services News
1 |
Building The No 3 Diagnostic Imaging PlayerJun 19 2024 - Small Caps |
2 |
Capitol Health’s Higher Margin OutlookMar 13 2024 - Small Caps |
3 |
Treasure Chest: Ramsay Health CareOct 26 2023 - Treasure Chest |
4 |
Timing Seems Right For Alcidion GroupJun 21 2023 - Small Caps |
5 |
No Enthusiasm To Combine ACL & HealiusMar 21 2023 - Australia |
6 |
Dr Boreham’s Crucible: AlcidionDec 13 2022 - Small Caps |
7 |
No Straight Covid-Relief For Ramsay Health CareNov 15 2022 - Australia |
8 |
Dr Boreham’s Crucible: Mach7 TechnologiesNov 14 2022 - Small Caps |
9 |
Negative Industry Trends Impact Australian Clinical LabsAug 12 2022 - Small Caps |
10 |
Healius Offers Digital Carrot, Base Remains SoftMay 25 2022 - Australia |